Mycenax Biotech Statistics

Total Valuation

Mycenax Biotech has a market cap or net worth of TWD 7.76 billion. The enterprise value is 8.37 billion.

Market Cap	7.76B
Enterprise Value	8.37B

Important Dates

The last earnings date was Friday, March 14, 2025.

Earnings Date	Mar 14, 2025
Ex-Dividend Date	n/a

Share Statistics

Mycenax Biotech has 207.01 million shares outstanding. The number of shares has increased by 0.23% in one year.

Current Share Class	n/a
Shares Outstanding	207.01M
Shares Change (YoY)	+0.23%
Shares Change (QoQ)	+0.20%
Owned by Insiders (%)	1.33%
Owned by Institutions (%)	0.20%
Float	112.97M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	11.30
PB Ratio	3.84
P/TBV Ratio	3.91
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-17.92
EV / Sales	12.24
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-16.03

Financial Position

The company has a current ratio of 1.11, with a Debt / Equity ratio of 0.44.

Current Ratio	1.11
Quick Ratio	0.64
Debt / Equity	0.44
Debt / EBITDA	n/a
Debt / FCF	-1.69
Interest Coverage	-17.64

Financial Efficiency

Return on equity (ROE) is -20.90% and return on invested capital (ROIC) is -9.49%.

Return on Equity (ROE)	-20.90%
Return on Assets (ROA)	-8.08%
Return on Invested Capital (ROIC)	-9.49%
Return on Capital Employed (ROCE)	-17.05%
Revenue Per Employee	1.77M
Profits Per Employee	-1.21M
Employee Count	387
Asset Turnover	0.19
Inventory Turnover	10.44

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -3.85% in the last 52 weeks. The beta is 0.87, so Mycenax Biotech's price volatility has been lower than the market average.

Beta (5Y)	0.87
52-Week Price Change	-3.85%
50-Day Moving Average	42.01
200-Day Moving Average	47.94
Relative Strength Index (RSI)	30.31
Average Volume (20 Days)	231,409

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Mycenax Biotech had revenue of TWD 683.92 million and -467.13 million in losses. Loss per share was -2.27.

Revenue	683.92M
Gross Profit	-241.36M
Operating Income	-461.54M
Pretax Income	-469.59M
Net Income	-467.13M
EBITDA	-206.91M
EBIT	-461.54M
Loss Per Share	-2.27

Full Income Statement

Balance Sheet

The company has 276.87 million in cash and 883.39 million in debt, giving a net cash position of -606.53 million or -2.93 per share.

Cash & Cash Equivalents	276.87M
Total Debt	883.39M
Net Cash	-606.53M
Net Cash Per Share	-2.93
Equity (Book Value)	2.02B
Book Value Per Share	9.77
Working Capital	74.89M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -191.68 million and capital expenditures -330.43 million, giving a free cash flow of -522.11 million.

Operating Cash Flow	-191.68M
Capital Expenditures	-330.43M
Free Cash Flow	-522.11M
FCF Per Share	-2.52

Full Cash Flow Statement

Margins

Gross margin is -35.29%, with operating and profit margins of -67.48% and -68.30%.

Gross Margin	-35.29%
Operating Margin	-67.48%
Pretax Margin	-68.66%
Profit Margin	-68.30%
EBITDA Margin	-30.25%
EBIT Margin	-67.48%
FCF Margin	n/a

Dividends & Yields

Mycenax Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.23%
Shareholder Yield	-0.23%
Earnings Yield	-6.02%
FCF Yield	-6.73%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Mycenax Biotech has an Altman Z-Score of 3.82.

Altman Z-Score	3.82
Piotroski F-Score	n/a